| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000031060 |
| Receipt No. | R000035327 |
| Official scientific title of the study | Prognostic and effect predictive factors of multimodality treatment for gastric cancer |
| Date of disclosure of the study information | 2018/02/20 |
| Last modified on | 2018/04/11 (Ver. 2) |
| Basic information | |||
| Official scientific title of the study | Prognostic and effect predictive factors of multimodality treatment for gastric cancer | ||
| Title of the study (Brief title) | Prognostic and effect predictive factors of multimodality treatment for gastric cancer | ||
| Region |
|
||
| Condition | |||
| Condition | Gastric cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of the research is to clarify the prognostic end effect predictive factors of multimodality treatment for the patients with gastric cancer |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Overall survival |
| Key secondary outcomes | Recurrence rate
Progression free survival Overall objective response rate Side effects of chemotherapy perioperative complication |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Gastric cancer | |||
| Key exclusion criteria | Patients with poorer prognosis less than three months. Patients who decline the offer to use the data | |||
| Target sample size | 500 | |||
| Research contact person | |
| Name of lead principal investigator | Masazumi Takahashi |
| Organization | Yokohama Municipal Citizen's Hospital |
| Division name | Division of Gastroenterological Surgery |
| Address | Okazawa-cho 56, hodogaya-ku, Yokohama |
| TEL | 045-331-1961 |
| ma06-takahashi@city.yokohama.jp | |
| Public contact | |
| Name of contact person | Masazumi Takahashi |
| Organization | Yokohama Municipal Citizen's Hospital |
| Division name | Division of Gastroenterological Surgery |
| Address | Okazawa-cho 56, hodogaya-ku, Yokohama |
| TEL | 045-331-1961 |
| Homepage URL | |
| ma06-takahashi@city.yokohama.jp | |
| Sponsor | |
| Institute | Yokohama Municipal Citizen's Hospital, Division of Gastroenterological Surgery |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yokohama Municipal Citizen's Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立市民病院(神奈川県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | This is a cohort study. Patients who were diagnosed as gastric cancer from 1999/4/1 to 2024/3/31 are calculated to this study. The endpoints are as follows.
1. Treatment (chemotherapy only, chemotherapy after operation, operation after chemotherapy, with of without radiation therapy) 2. Death investigation (date of death, cause of death) 3. Selected chemotherapy and numbers of course 4. Side-effects of chemotherapy according to the CTCAE guidelines.(RBC, Hb, WBC, Plt, TP, Alb, AST, ALT, gamma GTP, BUN, Crt %lymphocte, %monocyte 5. Prognostic and effect predictive factors, %lymphocte, %monocyte, %neutrocte, Number of Plt, CRP, sIL-2R, Alb 6. Timing of operation and operation method 7. Operative complications according to the Clavien-Dindo classification. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035327 |